{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=mitoxantrone+hydrochloride+%28DHAD%29&page=8",
    "query": {
      "intervention": "mitoxantrone hydrochloride (DHAD)",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 176,
    "total_pages": 18,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=mitoxantrone+hydrochloride+%28DHAD%29&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=mitoxantrone+hydrochloride+%28DHAD%29&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T02:19:05.830Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00016016",
      "title": "Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Untreated Adult Acute Lymphoblastic Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "alvocidib",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2001-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-10-08",
      "last_synced_at": "2026-10-15T02:19:05.830Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00016016"
    },
    {
      "nct_id": "NCT00208975",
      "title": "Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2002-07",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2012-06-28",
      "last_synced_at": "2026-10-15T02:19:05.830Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00208975"
    },
    {
      "nct_id": "NCT00186875",
      "title": "Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Lymphoma, Lymphoblastic"
      ],
      "interventions": [
        {
          "name": "Etoposide, cytarabine, vincristine, dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "methotrexate, teniposide, PEG-asparaginase",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine",
          "type": "DRUG"
        },
        {
          "name": "L-asparaginase, erwinia asparaginase",
          "type": "DRUG"
        },
        {
          "name": "chemotherapy, intrathecal chemotherapy, steroid therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Hematopoietic Stem Cell Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Natural Killer (NK) Cell Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 47,
      "start_date": "2003-11",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2017-07-28",
      "last_synced_at": "2026-10-15T02:19:05.830Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Memphis, Tennessee",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00186875"
    },
    {
      "nct_id": "NCT00058084",
      "title": "Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate",
        "Recurrent Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ixabepilone",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 80,
      "start_date": "2003-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-02-23",
      "last_synced_at": "2026-10-15T02:19:05.830Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00058084"
    },
    {
      "nct_id": "NCT06007911",
      "title": "Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed Adult AML",
        "Refractory AML"
      ],
      "interventions": [
        {
          "name": "Navitoclax Dose Level 1",
          "type": "DRUG"
        },
        {
          "name": "Navitoclax Dose Level 0",
          "type": "DRUG"
        },
        {
          "name": "Navitoclax Dose Level 2",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax Dose Level -1",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax Dose Levels 0 to 2",
          "type": "DRUG"
        },
        {
          "name": "Cladribine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (Cladribine Low Dose Cytarabine Backbone)",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (CLAG-M Backbone)",
          "type": "DRUG"
        },
        {
          "name": "Mitoxantrone",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte Colony-Stimulating Factor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-08-31",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2024-08-13",
      "last_synced_at": "2026-10-15T02:19:05.830Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06007911"
    },
    {
      "nct_id": "NCT00003183",
      "title": "Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Hope Cancer Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 64,
      "start_date": "1997-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-10-15T02:19:05.830Z",
      "location_count": 2,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003183"
    },
    {
      "nct_id": "NCT01027923",
      "title": "IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Myeloid, Acute"
      ],
      "interventions": [
        {
          "name": "Plerixafor",
          "type": "DRUG"
        },
        {
          "name": "Mitoxantrone",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 6,
      "start_date": "2010-05",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2015-01-26",
      "last_synced_at": "2026-10-15T02:19:05.830Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01027923"
    },
    {
      "nct_id": "NCT00002674",
      "title": "Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "17 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "1994-10",
      "completion_date": "2000-03",
      "has_results": false,
      "last_update_posted_date": "2010-04-02",
      "last_synced_at": "2026-10-15T02:19:05.830Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002674"
    },
    {
      "nct_id": "NCT02907359",
      "title": "Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Leukemia, Myelomonocytic, Chronic"
      ],
      "interventions": [
        {
          "name": "Guadecitabine",
          "type": "DRUG"
        },
        {
          "name": "Treatment Choice",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Astex Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 417,
      "start_date": "2017-01-13",
      "completion_date": "2020-11-30",
      "has_results": true,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-10-15T02:19:05.830Z",
      "location_count": 22,
      "location_summary": "Duarte, California • Rancho Mirage, California • Fleming Island, Florida + 18 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Fleming Island",
          "state": "Florida"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02907359"
    },
    {
      "nct_id": "NCT00017563",
      "title": "Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 57,
      "start_date": "2000-09",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2017-04-28",
      "last_synced_at": "2026-10-15T02:19:05.830Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00017563"
    }
  ]
}